DGX vs RYTM · P/E 22, rev $5.94B vs rev $131.4M
Quest Diagnostics Incorporated (DGX) versus Rhythm Pharmaceuticals Inc (RYTM) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported RYTM revenue for 2026-06-30 was $131.4M. Net income was -$104.9M. RYTM currently screens at market cap $6.49B.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. RYTM currently screens at market cap $6.49B.
Not investment advice. Open the DGX and RYTM stock pages for the full models.
Not investment advice.